Multiple ligand docking by Glide: implications for virtual second-site screening.

Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently. Chem Soc Rev (2015) 1.74

Pharmacological potential of biogenic amine-polyamine interactions beyond neurotransmission. Br J Pharmacol (2013) 0.84

Principles and Overview of Sampling Methods for Modeling Macromolecular Structure and Dynamics. PLoS Comput Biol (2016) 0.78

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem (2004) 15.51

Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem (2006) 8.75

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (2009) 8.65

Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem (2004) 7.96

Cytochrome p450 and chemical toxicology. Chem Res Toxicol (2007) 4.49

Multiple molecular mechanisms for multidrug resistance transporters. Nature (2007) 3.96

Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A (2006) 3.74

Recent developments in fragment-based drug discovery. J Med Chem (2008) 3.30

Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des (2007) 2.46

Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol (2000) 1.87

Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. J Chem Inf Model (2009) 1.77

Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci U S A (1998) 1.74

Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol (2005) 1.70

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem (2006) 1.64

Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. J Biol Chem (2005) 1.52

Cooperativity and biological complexity. Nat Chem Biol (2008) 1.52

Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des (2010) 1.48

Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein. EMBO J (2004) 1.47

Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol (2002) 1.19

Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem (2010) 1.17

Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand-induced structural response through alpha-helical repositioning. Biochemistry (2009) 1.14

Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem (2008) 1.14

Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry (2005) 1.12

Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc Natl Acad Sci U S A (2000) 1.12

Role of active site water molecules and substrate hydroxyl groups in oxygen activation by cytochrome P450 158A2: a new mechanism of proton transfer. J Biol Chem (2005) 1.10

Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry (2001) 1.09

Cooperative properties of cytochromes P450. Pharmacol Ther (2009) 1.09

Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des (2007) 1.08

Crystal structures and catalytic mechanism of cytochrome P450 StaP that produces the indolocarbazole skeleton. Proc Natl Acad Sci U S A (2007) 1.07

Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry (2004) 1.00

Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol (2008) 0.98

Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys (2005) 0.97

Cooperativity in oxidation reactions catalyzed by cytochrome P450 1A2: highly cooperative pyrene hydroxylation and multiphasic kinetics of ligand binding. J Biol Chem (2008) 0.97

Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem (2009) 0.94

Cooperative binding of acetaminophen and caffeine within the P450 3A4 active site. Chem Res Toxicol (2007) 0.94

Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc Natl Acad Sci U S A (2001) 0.93

Multiple-ligand binding in CYP2A6: probing mechanisms of cytochrome P450 cooperativity by assessing substrate dynamics. Biochemistry (2008) 0.93

In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther (2003) 0.93

NMR studies of ligand binding to P450(eryF) provides insight into the mechanism of cooperativity. Biochemistry (2006) 0.92

Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes. J Chem Inf Model (2010) 0.92

Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein. J Comput Chem (2010) 0.90

Temperature adaptation of glutathione S-transferase P1-1. A case for homotropic regulation of substrate binding. J Biol Chem (1999) 0.90

Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci (2001) 0.88

Predictive models of CYP3A4 Heteroactivation: in vitro-in vivo scaling and pharmacophore modeling. J Pharmacol Exp Ther (2004) 0.88

Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther (2003) 0.88

How well can fragments explore accessed chemical space? A case study from heat shock protein 90. J Med Chem (2011) 0.87

Homotropic versus heterotopic cooperativity of cytochrome P450eryF: a substrate oxidation and spectral titration study. Drug Metab Dispos (2003) 0.87

Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines. J Biol Chem (2009) 0.86

Activators of P-glycoprotein: Structure-activity relationships and investigation of their mode of action. ChemMedChem (2009) 0.85

Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J Med Chem (2011) 0.85

Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther (1999) 0.84

Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. J Med Chem (2007) 0.82

Discovery of a novel Hsp90 inhibitor by fragment linking. ChemMedChem (2010) 0.82

In vitro and in vivo activation of oxidative drug metabolism by flavonoids. J Pharmacol Exp Ther (1984) 0.81

Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. Drug Metab Dispos (2007) 0.75

Contributions of molecular properties to drug promiscuity. J Med Chem (2013) 0.95

Thermodynamics of fragment binding. J Chem Inf Model (2012) 0.89

Fragment-based lead discovery on G-protein-coupled receptors. Expert Opin Drug Discov (2013) 0.83

How are fragments optimized? A retrospective analysis of 145 fragment optimizations. J Med Chem (2013) 0.82

Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat (2012) 0.80

The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. Am J Pathol (2012) 0.80

Comparative evaluation of pK(a) prediction tools on a drug discovery dataset. J Pharm Biomed Anal (2012) 0.77

The impact of molecular dynamics sampling on the performance of virtual screening against GPCRs. J Chem Inf Model (2013) 0.77

Quinolinyl- and phenantridinyl-acetamides as bradykinin B1 receptor antagonists. Bioorg Med Chem Lett (2012) 0.76

Erratum to: A desirability function-based scoring scheme for selecting fragment-like class A aminergic GPCR ligands. J Comput Aided Mol Des (2015) 0.75

Bradykinin B1 receptor antagonists: a patent update 2009 - 2012. Expert Opin Ther Pat (2012) 0.75

Structure-Based Consensus Scoring Scheme for Selecting Class A Aminergic GPCR Fragments. J Chem Inf Model (2016) 0.75

A desirability function-based scoring scheme for selecting fragment-like class A aminergic GPCR ligands. J Comput Aided Mol Des (2014) 0.75